11/18
08:50 am
ymab
Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $23.00 price target on the stock.
Medium
Report
Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $23.00 price target on the stock.
11/18
06:57 am
ymab
Institutional investors in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) lost 25% last week but have reaped the benefits of longer-term growth [Yahoo! Finance]
Medium
Report
Institutional investors in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) lost 25% last week but have reaped the benefits of longer-term growth [Yahoo! Finance]
11/15
03:26 pm
ymab
Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $22.00 price target on the stock.
Low
Report
Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $22.00 price target on the stock.
11/9
06:17 am
ymab
Y-mAbs Therapeutics Inc (YMAB) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges ... [Yahoo! Finance]
Low
Report
Y-mAbs Therapeutics Inc (YMAB) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges ... [Yahoo! Finance]
11/8
06:35 am
ymab
Y-mAbs Reports Third Quarter 2024 Financial Results and Recent Corporate Developments
Low
Report
Y-mAbs Reports Third Quarter 2024 Financial Results and Recent Corporate Developments
11/7
07:18 am
ymab
What To Expect From Y-mAbs Therapeutics Inc (YMAB) Q3 2024 Earnings [Yahoo! Finance]
Low
Report
What To Expect From Y-mAbs Therapeutics Inc (YMAB) Q3 2024 Earnings [Yahoo! Finance]
11/4
07:42 am
ymab
Y-mAbs and Nobelpharma Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) in Japan [Yahoo! Finance]
Neutral
Report
Y-mAbs and Nobelpharma Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) in Japan [Yahoo! Finance]
11/4
07:35 am
ymab
Y-mAbs and Nobelpharma Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) in Japan
Neutral
Report
Y-mAbs and Nobelpharma Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) in Japan
11/1
11:55 am
ymab
Will Y-mAbs Therapeutics, Inc. (YMAB) Report Negative Earnings Next Week? What You Should Know [Yahoo! Finance]
Low
Report
Will Y-mAbs Therapeutics, Inc. (YMAB) Report Negative Earnings Next Week? What You Should Know [Yahoo! Finance]
10/25
07:05 am
ymab
Y-mAbs Announces Third Quarter 2024 Conference Call and Webcast
Low
Report
Y-mAbs Announces Third Quarter 2024 Conference Call and Webcast
10/21
03:07 pm
ymab
Y-mAbs Therapeutics: Slow But Steady Prospect In Rare Cancers [Seeking Alpha]
Low
Report
Y-mAbs Therapeutics: Slow But Steady Prospect In Rare Cancers [Seeking Alpha]
10/1
07:09 am
ymab
US lawmakers ask Mexican president-elect to address Chinese vehicle concerns [Yahoo! Finance Canada]
Low
Report
US lawmakers ask Mexican president-elect to address Chinese vehicle concerns [Yahoo! Finance Canada]
10/1
07:05 am
ymab
Y-mAbs to Participate in Upcoming Investor Conferences in October
Low
Report
Y-mAbs to Participate in Upcoming Investor Conferences in October
9/25
09:42 am
ymab
While shareholders of Y-mAbs Therapeutics (NASDAQ:YMAB) are in the black over 1 year, those who bought a week ago aren't so fortunate [Yahoo! Finance]
Neutral
Report
While shareholders of Y-mAbs Therapeutics (NASDAQ:YMAB) are in the black over 1 year, those who bought a week ago aren't so fortunate [Yahoo! Finance]
9/10
09:12 am
ymab
Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $23.00 price target on the stock.
Low
Report
Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $23.00 price target on the stock.
9/9
01:03 pm
ymab
Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $20.00 price target on the stock.
Low
Report
Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $20.00 price target on the stock.
9/6
07:30 am
ymab
Y-mAbs Presents Neuroblastoma Research on Naxitamab and SADA PRIT Technology Platform at AACR Special Conference on Advances in Pediatric Cancer Research
Low
Report
Y-mAbs Presents Neuroblastoma Research on Naxitamab and SADA PRIT Technology Platform at AACR Special Conference on Advances in Pediatric Cancer Research
9/3
08:38 am
ymab
Y-mAbs to Participate in Upcoming Investor Conferences in September [Yahoo! Finance]
Medium
Report
Y-mAbs to Participate in Upcoming Investor Conferences in September [Yahoo! Finance]
9/3
08:32 am
ymab
Y-mAbs to Participate in Upcoming Investor Conferences in September
Medium
Report
Y-mAbs to Participate in Upcoming Investor Conferences in September